



21FW

Patent Application
Attorney's Docket No. PC25367A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 7th day of January 2005.

By

Madeline Deveran

(Signature of person mailing)

Madeline Deveran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David Hepworth :

APPLICATION NO.: 10/800,065 : Examiner: To Be Assigned

FILING DATE: March 12, 2004 : Group Art Unit: 1614

TITLE: 3(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic Acid :
Derivatives as NEP Inhibitors

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: Jan 7, 2005
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811

